The probable antitumour action of ranopterinneopterin may be mediated by two mechanisms: a direct action on tumour cells by activated and NO producing cytotoxic macrophages (1, 2) or indirectly by activation of host T-cell immune and defence mechanisms ( 1, 3, 4) . The possibility that neopterin might alter tumour process was also supported by data ( 5) on elevated neopterin concentrations in body fluids during malignant disease suggesting that high neopterin levels might reflect the host's response to tumour cells or virally transformed cells. As can be concluded from in vitro data neopterin release is coupled with early events of activated cell-mediated immunity (CMI) and results support the notion that persistent preactivation of eMI without destruction of tumour cells may enhance tumour growth (3) . However, in vitro tests do not necessarily reflect the in vivo situation and an alternative approach is to test this assumption in vivo -in a variety of experiments with tumour bearing animals.
The aim of the present research was to examine in vivo the biological activity of the exogeneously administered ranopterin -neopterin on the appearance (transplantability -T), tumour growth inhibition (TGI ) and mortality (M) of animals bearers of progressing myeloid tumours induced by Graffi virus in hamsters. Material and methods. Forty experimental animals -8 -10 week old and newborn hamsters of both sexes were used. Controls (untrated animals), and experimantal ones -tumour-bearing (including i.p. inoculated with neopterin at a dose 30 ~g/hamster at different days -21 " and 42'h before the tumour implantation) were examined paralelly at the same time intervals.
Myeloid tumour was originally induced in newborn hamsters by inoculation of Graffi -virus (6).
Transplantation of the myeloid tumour (MT) induced by Graffi virus was performed by single subcutaneous inoculation of viable tumour cells isolated mechanically from removed and dis aggregated tumours by a method described earlier (6,7 ) . After a trypan-blue test for cell viability, the dose of 5 x 10 4 cells per animal, estimated as optimal in our investigation, was s.c. injected (in other studies a single s .c. inoculation of 1 0 4 and/or 1,5 x 10 4 viable tumour cells/per animal was the dose estimated as optimal). Transplantibility (T) of the tumour was assayed on 11, 15, 18, and 22 days after the implantation of the tumour cells.
Tumour growth (TG) was determined at regulated intervals by measuring tumours larger and smaller diameters in mm., and by calculating of tumour diameter from these values . The inhibition of tumour growth (TGI) was calculated by the formula:
A-B TGI% = --x 100; A A-diameter ( mm ) of conu'ol animals; B-diameter (mm ) of experimental animals
The inhibitory effect of ranopterin neopterin was considered as positive when the TGI was 50% or more (6-11).
Mortality (M) of the animals was determined at 35-37, 39, 41, 43-45 and 47 days of the observation as a percent of died to all implanted animals.
The cellular composition of blood smears was characterized in every case at the 10 days intervals: the staining was performed by Gimsa and by a method of Zvetkova and Zvetkov (12 ) .
Results and discussion . The inoculation of 5 X 10 4 live tumour cells developed palpable tumours after 10-+5 days. In other experimental models ( 7-11) with lowest tumour cells inoculated (e.g. the tumours developed later (e .g. after 15+-5 days). The tumours grew to 40-50 mm in diameter, very soon gave methastases and killed the host at 30+-10 days. No tumour regressed spontaneously and all hamster that developed tumours died of tumour progression.
Our ohservations showed a decreased T of the ranopterin neopterin-pretreated animals : the percent of transplantability was 4-5 fold lower in all two neopterin -treated experimental groups compared to the controls (Fig. 1 ) .
The examinations of tumour size ( diameters ) showed that the neopterin pretreatment inhibited tumour growth 100% till the 11 day of the observation. The TGI was well expressed in two experimental groups during the whole period of observations: 50-58%, 20-30% and 15-20% to the 35 day of the experiment (Fig. 2) . One can see that the TGI was lowest for the second experimental group (neopterin-pretreated animals 42 days before tumour implantation). The differences between tumour size of the control (untreated ) and neopterin-pretreated experimental groups gradually decreased till the 35 th day: 58%,
Per cen t tr a n s pl on fi b _ il_ l ty ' -_ _ _ ,-, I - 30% and 10% respectively (Fig. 2) . The data on the percent of transplantability correlated with the results on the TGI and with the results of the mean survival time (MST ): 12 days prolongation of the MST was established for the animals of first group and 10 days -for the second one (Fig. 3) . The death rate data (Fig. 3 ) also illustrated the protective effect of the neopterin pretreatment -no mortality until 39 th day post tumour implantation and 50% mortality at the 40 th day of observation for the animals of the first experimental group .
Inhibition of Tu growth In
The results illustrated the protective role of the ranopterin-neopterin on the neoplasia development In cases when experimental tumour-bearing animals were neopterin-pretreted 21-42 days before tumour implantation. The data pointed out that in our experimental conditions the ranopterin-neopterin can act as m yeloid tumour preventive drug and that the single neopterin pretreatment in a dose 30 f.lg/ per animal, 21 days before tumour implantation has the best protective effect against tumour progression instead of fact that mechanisms assumed for its antitumour activity ( 1-4 ) are still unclear. Such an effect was absent when neopterin treatment of ?a,-c 9n f m orio :ity :;: . . . The precise mechanisms by which the neopterin pretreatment could modify tumour growth are probably indirect -by activation/pre-activation of the host immune system ( 1-4) before the tumour implantation: as a result the tumour cells became more sensitive to the host response. This possibility was supported by our data that one population of small T -lymphocytes appeared in a very high percent in the peripheral blood of neopterin-pretreated tumours-bearing animals (Fig. 4) . This cytotoxic T-cell population was only persistent or a bsent in the peripheral blood smears of the neopterin-untreated controls (tumour-bearing ani mals) and earlier was described by u s ( 13, 14 ) in the peripheral blood of cancer patients ( 13 ) as ..
Zvetkova et at.:
Protecti" e e tlect of rano pterin neopterin well as in preneoplasias ( 14) as aT-cell population which participates in the immunogenic antitumour mechanisms. In other experimental models with subcutaneo u s immunization the antigen in the same doze ( 30 Ilg) was given twice at a 21-day interval ( 15 ) . In a model of healthy mice we also observed T-cell proliferation and enhanced T -immune response under in vivo influence of ranopterin -n e opterin (4) . A direct anti tumour action of neopterinactivated in vivo and NO-producing macrophage subpopulations (2 ) could be also discussed as another possible precise mechanism by which neopterin can modify the growth of tumour cells . In addition more recently the very important biological role of neopterin as an endogeneous antioxidant, modulating the cellular oxidantantioxidant balance, has been reported ( 15) . It may be also of importance in diseases associated with an activation of the cellular immune system that neopterin derivatives, modulating the cellular oxidant-antioxidant balance as well as the expression of the inducible nitric oxide synthase (iNOS) gene, induce apoptotic cell death. Hoffman et al. (17) showed that one intracellular mechanism for neopte rin-induced iNOS gene expression is the activation of nuclear factor-kB . probably involved in the mechanisms of cell proliferation of mouse bone marrow progenitors described by us (4, (18) (19) (20) in vitro and in vivo under the biological action of ranopterines -pterin-6 carbonic acid (Pt-6-COOH) and neopterin, acting as granulocyte-macrophageal colony-stimulating factor (GM-CSF) and lymphocyte proliferative factor (LyPF), respectively. The direct effect of these compounds on bone marrow MG-anf Ly progeniters as nuclear cell proliferation factors is probably related to the action of increased intracellular GTP (18, 19) .
Direct effects of some pteridine derivatives as neopterin on growth factors and on other cell signalling pathways, particularly together with cGMP, is also possible, because it has recently been shown (21) that these substances, namely neopterin, 7,8-dihydroneopterin and cyclic guanosine monophosphate (cGMP) would significantly enhance the risk of c-fos gene expression and therefore promote tumour growth and development. From this point of view remain to be clarified the data on the simultaneous elevation of macrophage colony-stimulating factor (M-CSF) and neopterin concentrations in cancer patients where a good correlation of elevated neopterin levels with a stage and poor prognosis of disease had been also demonstrated (22) .
